242 related articles for article (PubMed ID: 22039593)
1. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
Blake KV; Prilla S; Accadebled S; Guimier M; Biscaro M; Persson I; Arlett P; Blackburn S; Fitt H
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1021-9. PubMed ID: 22039593
[TBL] [Abstract][Full Text] [Related]
2. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
3. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
4. Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
Blake KV; Devries CS; Arlett P; Kurz X; Fitt H;
Pharmacoepidemiol Drug Saf; 2012 Jul; 21(7):690-696. PubMed ID: 22522622
[TBL] [Abstract][Full Text] [Related]
5. [The new pharmacovigilance legislation in practice].
Broekmans AW; Mol PG
Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
[TBL] [Abstract][Full Text] [Related]
6. Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation.
Pacurariu A; Plueschke K; McGettigan P; Morales DR; Slattery J; Vogl D; Goedecke T; Kurz X; Cave A
BMJ Open; 2018 Sep; 8(9):e023090. PubMed ID: 30185579
[TBL] [Abstract][Full Text] [Related]
7. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.
Engel P; Almas MF; De Bruin ML; Starzyk K; Blackburn S; Dreyer NA
Br J Clin Pharmacol; 2017 Apr; 83(4):884-893. PubMed ID: 27780289
[TBL] [Abstract][Full Text] [Related]
8. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
[TBL] [Abstract][Full Text] [Related]
9. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
[TBL] [Abstract][Full Text] [Related]
10. Regulating medicines in Europe: the European Medicines Agency, marketing authorisation, transparency and pharmacovigilance.
Permanand G; Mossialos E; McKee M
Clin Med (Lond); 2006; 6(1):87-90. PubMed ID: 16521363
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
[TBL] [Abstract][Full Text] [Related]
12. Obstacles to transparency over pharmacovigilance data within the EMA.
Prescrire Int; 2015 Nov; 24(165):278-9. PubMed ID: 26688911
[TBL] [Abstract][Full Text] [Related]
13. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
[TBL] [Abstract][Full Text] [Related]
14. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
[TBL] [Abstract][Full Text] [Related]
15. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
16. [The role of the Committee for Medicinal Products for Human Use (CHMP) in the European centralised procedure].
Enzmann H; Schneider C
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):731-9. PubMed ID: 18584106
[TBL] [Abstract][Full Text] [Related]
17. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
Woodward KN
J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
[TBL] [Abstract][Full Text] [Related]
18. Improving the Safety of Medicines in the European Union: From Signals to Action.
Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
[TBL] [Abstract][Full Text] [Related]
19. Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators.
Pacurariu A; Plueschke K; Olmo CA; Kurz X
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):823-826. PubMed ID: 29749086
[TBL] [Abstract][Full Text] [Related]
20. Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database.
Plueschke K; Jonker C; Strassmann V; Kurz X
Drug Saf; 2022 Jul; 45(7):747-754. PubMed ID: 35729468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
